Switch theme
Sign up to access all valuation multiples
Hipromine SA is a European scale supplier of an alternative protein produced through innovative, proprietary technology of industrial insect breeding. The company’s offer is directed mainly to the market of pet food and fodder for fish farming, as well as livestock and horticulture.
2015
n/a
Last FY Revenue $0.9M
Last FY EBITDA -$8.3M
$86.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hipromine achieved revenue of $0.9M and an EBITDA of -$8.3M.
Hipromine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hipromine valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | XXX | -$1.1M | XXX | XXX | XXX |
| Gross Margin | XXX | -124% | XXX | XXX | XXX |
| EBITDA | XXX | -$8.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -918% | XXX | XXX | XXX |
| EBIT | XXX | -$11.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1233% | XXX | XXX | XXX |
| Net Profit | XXX | -$12.9M | XXX | XXX | XXX |
| Net Margin | XXX | -1424% | XXX | XXX | XXX |
| Net Debt | XXX | $39.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hipromine's stock price is PLN 162 (or $43).
Hipromine has current market cap of PLN 172M (or $45.6M), and EV of PLN 327M (or $86.8M).
See Hipromine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86.8M | $45.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hipromine has market cap of $45.6M and EV of $86.8M.
Hipromine's trades at 95.9x EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate Hipromine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hipromine's P/E ratio is not available.
See valuation multiples for Hipromine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.6M | XXX | $45.6M | XXX | XXX | XXX |
| EV (current) | $86.8M | XXX | $86.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 95.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -7.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHipromine's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hipromine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hipromine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hipromine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -918% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1109% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Agthia Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Acomo | XXX | XXX | XXX | XXX | XXX | XXX |
| ForFarmers | XXX | XXX | XXX | XXX | XXX | XXX |
| JDE Peets | XXX | XXX | XXX | XXX | XXX | XXX |
| Sligro Food Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hipromine acquired XXX companies to date.
Last acquisition by Hipromine was XXXXXXXX, XXXXX XXXXX XXXXXX . Hipromine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hipromine founded? | Hipromine was founded in 2015. |
| Where is Hipromine headquartered? | Hipromine is headquartered in Poland. |
| Is Hipromine publicy listed? | Yes, Hipromine is a public company listed on WAR. |
| What is the stock symbol of Hipromine? | Hipromine trades under HPM ticker. |
| When did Hipromine go public? | Hipromine went public in 2022. |
| Who are competitors of Hipromine? | Similar companies to Hipromine include e.g. Agthia Group, Acomo, ForFarmers, JDE Peets. |
| What is the current market cap of Hipromine? | Hipromine's current market cap is $45.6M |
| Is Hipromine profitable? | Yes, Hipromine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
